Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on healthcare industries. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until the deal closes, the Microfluidics unit will continue to operate as part of Standard BioTools. This divestiture marks a strategic step for the company to streamline its portfolio. Standard BioTools operates in the life science tools industry, providing next-generation solutions and instruments for biomedical research.
